Literature DB >> 33673029

Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones.

Béla Kocsis1, Dániel Gulyás1, Dóra Szabó1.   

Abstract

Pseudomonas aeruginosa high-risk clones are disseminated worldwide and they are common causative agents of hospital-acquired infections. In this review, we will summarize available data of high-risk P. aeruginosa clones from confirmed outbreaks and based on whole-genome sequence data. Common feature of high-risk clones is the production of beta-lactamases and among metallo-beta-lactamases NDM, VIM and IMP types are widely disseminated in different sequence types (STs), by contrast FIM type has been reported in ST235 in Italy, whereas GIM type in ST111 in Germany. In the case of ST277, it is most frequently detected in Brazil and it carries a resistome linked to blaSPM. Colistin resistance develops among P. aeruginosa clones in a lesser extent compared to other resistance mechanisms, as ST235 strains remain mainly susceptible to colistin however, some reports described mcr positive P. aeurigonsa ST235. Transferable quinolone resistance determinants are detected in P. aeruginosa high-risk clones and aac(6')-Ib-cr variant is the most frequently reported as this determinant is incorporated in integrons. Additionally, qnrVC1 was recently detected in ST773 in Hungary and in ST175 in Spain. Continuous monitoring and surveillance programs are mandatory to track high-risk clones and to analyze emergence of novel clones as well as novel resistance determinants.

Entities:  

Keywords:  Pseudomonas aeruginosa; multiresistance; nosocomial pathogen

Year:  2021        PMID: 33673029     DOI: 10.3390/microorganisms9020359

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  6 in total

1.  Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.

Authors:  Alba Ruedas-López; Isaac Alonso-García; Cristina Lasarte-Monterrubio; Paula Guijarro-Sánchez; Eva Gato; Juan Carlos Vázquez-Ucha; Juan Andrés Vallejo; Pablo Arturo Fraile-Ribot; Begoña Fernández-Pérez; David Velasco; José María Gutiérrez-Urbón; Marina Oviaño; Alejandro Beceiro; Concepción González-Bello; Antonio Oliver; Jorge Arca-Suárez; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.938

2.  Genomic-based transmission analysis of carbapenem-resistant Pseudomonas aeruginosa at a tertiary care centre in Cologne (Germany) from 2015 to 2020.

Authors:  Andreas F Wendel; Monika Malecki; Frauke Mattner; Kyriaki Xanthopoulou; Julia Wille; Harald Seifert; Paul G Higgins
Journal:  JAC Antimicrob Resist       Date:  2022-05-20

3.  Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.

Authors:  Yulin Zhang; Jiankang Zhao; Jiajing Han; Yanyan Fan; Zhujia Xiong; Xiaohui Zou; Binbin Li; Xinmeng Liu; Ziyao Li; Binghuai Lu; Bin Cao
Journal:  Microbiol Spectr       Date:  2022-03-22

4.  The First Saudi Report of Novel and Common Mutations in the gyrA and parC Genes Among Pseudomonas Spp. Clinical Isolates Recovered from Taif Area.

Authors:  Mohamed F El-Badawy; Emad M Eed; Asmaa S Sleem; Azza A K El-Sheikh; Ibrahim A Maghrabi; Sayed F Abdelwahab
Journal:  Infect Drug Resist       Date:  2022-07-16       Impact factor: 4.177

5.  Genomic Characterization of Carbapenem-Non-susceptible Pseudomonas aeruginosa Clinical Isolates From Saudi Arabia Revealed a Global Dissemination of GES-5-Producing ST235 and VIM-2-Producing ST233 Sub-Lineages.

Authors:  Michel Doumith; Sarah Alhassinah; Abdulrahman Alswaji; Maha Alzayer; Essa Alrashidi; Liliane Okdah; Sameera Aljohani; Hanan H Balkhy; Majed F Alghoribi
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

6.  Resistance mechanisms and genetic relatedness among carbapenem-resistant Pseudomonas aeruginosa isolates from three major hospitals in Hanoi, Vietnam (2011-15).

Authors:  Hai Anh Tran; Thi Ngoc Bich Vu; Son Tung Trinh; Dieu Linh Tran; Ha My Pham; Thi Hong Hanh Ngo; Minh Thao Nguyen; Nhu Duong Tran; Duy Thai Pham; Duc Anh Dang; Keigo Shibayama; Masato Suzuki; Lay-Myint Yoshida; Hong Son Trinh; Viet Thanh Le; Phuong Thom Vu; Thi Vu Nga Luu; Anne-Laure Bañuls; Khanh Linh Trinh; Van Anh Tran; Huy Hoang Tran; H Rogier van Doorn
Journal:  JAC Antimicrob Resist       Date:  2021-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.